AVTX
Avalo Therapeutics, Inc. NASDAQ$13.78
Mkt Cap $155.6M
52w Low $3.39
60.0% of range
52w High $20.72
50d MA $15.21
200d MA $14.24
P/E (TTM)
-2.4x
EV/EBITDA
-3.2x
P/B
2.2x
Debt/Equity
0.0x
ROE
-94.2%
P/FCF
-4.7x
RSI (14)
—
ATR (14)
—
Beta
0.94
50d MA
$15.21
200d MA
$14.24
Avg Volume
686.1K
About
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflam…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -1.54 | -0.37 | +76.0% | 13.50 | +0.0% | -0.4% | +3.3% | +3.3% | +2.9% | +3.2% | +7.4% | — |
| Nov 6, 2025 | AMC | -1.67 | -2.19 | -31.1% | 15.42 | -0.6% | -2.4% | -1.3% | +0.5% | +0.1% | -4.5% | +26.1% | — |
| Aug 7, 2025 | AMC | -1.43 | -1.92 | -34.3% | 8.35 | +4.9% | +6.9% | +7.9% | +12.1% | +8.6% | +7.2% | +36.6% | — |
| May 12, 2025 | AMC | -1.07 | -1.25 | -16.8% | 4.00 | +0.0% | -8.0% | -10.0% | -3.5% | -2.2% | +0.0% | +17.8% | — |
| Apr 4, 2025 | AMC | 0.58 | -7.95 | -1470.7% | 5.80 | -1.6% | -0.7% | -5.3% | -12.1% | -14.8% | -15.5% | -13.4% | — |
| Nov 7, 2024 | AMC | -1.19 | -2.83 | -137.8% | 12.91 | -7.0% | +3.1% | +2.6% | -0.8% | +3.8% | +4.4% | -18.7% | — |
| Aug 12, 2024 | AMC | -6.70 | -14.07 | -110.0% | 9.90 | +5.8% | -0.2% | +2.7% | -6.1% | -8.4% | -6.6% | -17.2% | — |
| Jul 11, 2024 | AMC | — | -141.14 | — | 12.00 | +4.2% | +1.3% | +5.4% | +4.2% | +8.2% | +4.2% | -17.5% | — |
| May 13, 2024 | AMC | -1.18 | -5.98 | -406.8% | 10.82 | -3.4% | -2.0% | -4.0% | -10.9% | -11.4% | +2.6% | +6.2% | — |
| Nov 9, 2023 | AMC | -261.90 | -26.19 | +90.0% | 23.52 | -1.0% | -8.2% | -7.1% | +1.0% | +1.0% | -6.1% | -58.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | BTIG | Maintains | Buy → Buy | — | $13.66 | $13.54 | -0.9% | -2.3% | +1.8% | -2.3% | +5.6% | +5.6% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.45 | $14.26 | +6.0% | +3.7% | +3.7% | +3.3% | +3.6% | +11.0% |
| Mar 24 | BTIG | Maintains | Buy → Buy | — | $13.50 | $13.50 | +0.0% | -0.4% | +3.3% | +3.3% | +2.9% | +3.2% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.19 | $16.21 | +0.1% | -3.4% | -7.0% | -8.6% | -2.7% | +0.4% |
| Sep 29 | BTIG | Maintains | Buy → Buy | — | $10.80 | $13.30 | +23.1% | +20.6% | +17.7% | +20.0% | +20.4% | +24.1% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.76 | $9.84 | +0.8% | +16.1% | +21.7% | +21.2% | +19.9% | +15.3% |
| Mar 20 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.99 | $7.65 | -4.3% | +2.9% | -4.1% | -4.5% | +6.9% | +4.6% |
| Apr 16 | Oppenheimer | Upgrade | Perform → Outperform | — | $15.24 | $16.90 | +10.9% | +4.6% | -10.6% | -21.2% | -23.7% | -19.9% |
| Jun 26 | Oppenheimer | Downgrade | Outperform → Perform | — | $1060.80 | $182.88 | -82.8% | -88.7% | -90.3% | -90.4% | -91.6% | -92.0% |
| Jun 26 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $1060.80 | $182.88 | -82.8% | -88.7% | -90.3% | -90.4% | -91.6% | -92.0% |
Recent Filings
8-K · 1.01
!! High
Avalo Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Avalo Therapeutics agreed to a $15 million milestone buyout option, expanding its financial obligations and potentially diluting shareholder value depending on whether the option gets exercised.
Apr 28
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
AVTX's executive departure (item 5.02) signals potential leadership instability or strategic shifts that could impact operational execution and investor confidence in near-term performance.
Mar 27
8-K
Unknown — 8-K Filing
Avalo's $98 million cash position provides sufficient runway through 2028, reducing near-term financing risk and allowing investors to focus on clinical trial progress for its IL-1 inflammatory disease pipeline.
Mar 23
Data updated apr 24, 2026 8:04pm
· Source: massive.com